Abstract:
Background Fungal infections are one of the most common dermatological
issues worldwide. Candida species-caused fungal infections are frequent on the
cutaneous surface. Eberconazole (EBZ) has the strongest antifungal action
against Candida spp., the major source of fungal infections.
Method In the present study, the cold method followed by probe sonication
was used to create EBZ-loaded ethosomal dispersion. The solubility of ethosomes
in different lipids and surfactants was used to choose these components. Under
magnetic stirring, the dispersion was absorbed into a carbopol 934 gel. In
vitro antifungal activity was performed using the Agar well diffusion
method, and their topical effectiveness against pathogenic Candida
albicans was compared to that of a marketed formulation containing
EBZ.
Results Eberconazol incorporated into gel displayed sustained release in
an in vitro release assay. Based on the zone of inhibition diameters, EBZ
formulation was determined to be efficient against C. albicans when
compared to the commercialized cream and plain gel.
Conclusion Based on these findings, the current study found that EBZ
possesses significant antifungal efficacy against C. albicans.